Dr Reddy's Labs

Which are the latest news on Dr Reddy's Labs?

Why is Dr Reddys Laboratories Ltd falling/rising?

As of 05-Sep, Dr Reddys Laboratories Ltd's stock price is declining, currently at 1,154.00, with a total drop of -1.45% over three days and underperformance against the Sensex. The company faces negative financial results, including a -58.96% fall in profit before tax over the last four quarters, contributing to a year-to-date decline of -9.21% in stock value.

As of 05-Sep, Dr Reddys Laboratories Ltd is experiencing a decline in its stock price, currently at 1,154.00, reflecting a change of -1.0 (-0.09%). The stock has been on a downward trend, having fallen for three consecutive days and showing a total decline of -1.45% during this period. This consistent drop is compounded by the fact that the stock is trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a bearish trend.<BR><BR>In terms of performance relative to the market, Dr Reddys has underperformed against the benchmark Sensex over various periods, including a -7.93% return over the past year compared to the Sensex's -5.21%. Furthermore, the stock has shown a significant decline in investor participation, with delivery volume dropping by -64.98% against the 5-day average, suggesting reduced interest from investors.<BR><BR>The company's financial health is also a concern, as it has reported negative results for the last four consecutive quarters, including a substantial fall in profit before tax (PBT) of -58.96%. This has contributed to a year-to-date decline of -9.21% in stock value, which is worse than the benchmark's performance. Additionally, while the company maintains high management efficiency with a return on equity (ROE) of 15.68%, the overall sentiment remains negative due to the significant drop in profits, which have fallen by -43.3% over the past year.<BR><BR>Overall, the combination of declining stock performance, poor financial results, and reduced investor interest are key factors contributing to the falling stock price of Dr Reddys Laboratories Ltd.

Who are in the management team of Dr Reddy's Labs?

The management team of Dr Reddy's Labs includes G V Prasad (Co-Chairman & Managing Director), K Satish Reddy (Executive Chairman), and several independent directors such as Kalpana Morparia and Leo Puri, among others, overseeing the company's strategic direction and governance.

The management team of Dr Reddy's Labs includes the following key members:<BR><BR>1. **G V Prasad** - Co-Chairman & Managing Director<BR>2. **K Satish Reddy** - Executive Chairman<BR>3. **Kalpana Morparia** - Independent Director<BR>4. **Shikha Sanjaya Sharma** - Independent Director<BR>5. **Leo Puri** - Independent Director<BR>6. **K P Krishnan** - Independent Director<BR>7. **Pennv Wan** - Independent Director<BR>8. **K Randhir Singh** - Company Secretary & Compliance Officer<BR>9. **Arun M. Kumar** - Independent Director<BR>10. **Claudio Albrecht** - Independent Director<BR><BR>This team is responsible for overseeing the strategic direction and governance of the company.

What does Dr Reddy's Labs do?

Dr Reddy's Laboratories Limited is a global pharmaceutical company focused on providing affordable medicines, with a market cap of INR 97,658 Cr and reported net sales of 8,100 Cr and net profit of 444 Cr for June 2026. Key metrics include a P/E ratio of 30.00 and a dividend yield of 0.68%.

Overview:<BR>Dr Reddy's Laboratories Limited (DRL) is an integrated global pharmaceutical company committed to providing affordable and innovative medicines, operating within the Pharmaceuticals & Biotechnology industry and categorized as a Mid Cap.<BR><BR>History:<BR>Dr Reddy's Laboratories was incorporated in an unspecified year and has maintained its status as a key player in the pharmaceutical sector. The latest quarterly results reported net sales and profit for June 2026.<BR><BR>Financial Snapshot:<BR>- Net Sales: 8,100 Cr (Quarterly Results - Jun 2026)<BR>- Net Profit: 444 Cr (Quarterly Results - Jun 2026)<BR>- Market Cap: INR 97,658 Cr (Mid Cap)<BR><BR>Key Metrics:<BR>- P/E: 30.00<BR>- Industry P/E: 37<BR>- Dividend Yield: 0.68%<BR>- Debt Equity: 0.01<BR>- Return on Equity: 11.07%<BR>- Price to Book: 2.59<BR><BR>Contact Details:<BR>- Address: 8-2-337 Road No 3, Banjara Hills Hyderabad Telangana : 500034<BR>- Tel: 91-40-49002900<BR>- Email: shares@drreddys.com<BR>- Website: http://www.drreddys.com

Who are the peers of the Dr Reddy's Labs?

Dr Reddy's Labs' peers include Zydus Lifesci, Cipla, Laurus Labs, Lupin, Mankind Pharma, Aurobindo Pharma, Glenmark Pharma, Biocon, and Alkem Lab. In terms of management risk, growth, and capital structure, Zydus Lifesci and Lupin show excellent performance, while Dr Reddy's Labs has average growth and a 1-year return of -7.76%.

Peers: The peers of Dr Reddy's Labs are Zydus Lifesci., Cipla, Laurus Labs, Lupin, Mankind Pharma, Aurobindo Pharma, Glenmark Pharma, Biocon, Alkem Lab.<BR><BR>Quality Snapshot: Excellent management risk is observed at Zydus Lifesci., Cipla, Lupin, Mankind Pharma, Glenmark Pharma, and Alkem Lab, while Average management risk is found at Aurobindo Pharma and Biocon. Growth is Excellent for Zydus Lifesci. and Lupin, while Below Average growth is noted for Cipla, Laurus Labs, Aurobindo Pharma, and Alkem Lab, and Average growth is seen at Dr Reddy's Labs and Glenmark Pharma. Capital Structure is Excellent for Zydus Lifesci., Cipla, Mankind Pharma, Aurobindo Pharma, and Alkem Lab, while Average is noted for Laurus Labs, Good for Lupin and Glenmark Pharma, and Below Average for Biocon.<BR><BR>Return Snapshot: Laurus Labs has the highest 1-year return at 122.69%, while Cipla has the lowest at -10.92%. Dr Reddy's Labs' 1-year return is -7.76%, which is higher than Cipla's but lower than Laurus Labs'. Additionally, Aurobindo Pharma and Dr Reddy's Labs have negative six-month returns.

How big is Dr Reddy's Labs?

As of 31st August, Dr Reddys Laboratories Ltd has a market capitalization of 97,658.00 Cr, with recent Net Sales of 33,227.90 Cr and a Net Profit of 3,222.20 Cr. Shareholder's Funds are 37,891.50 Cr and Total Assets are valued at 55,904.40 Cr.

As of 31st August, Dr Reddys Laboratories Ltd has a market capitalization of 97,658.00 Cr, categorizing it as a Mid Cap company.<BR><BR>In the latest four quarters, the company reported Net Sales of 33,227.90 Cr and a Net Profit of 3,222.20 Cr.<BR><BR>For the reporting period of March 2026, Shareholder's Funds amounted to 37,891.50 Cr, while Total Assets were valued at 55,904.40 Cr.

Are Dr Reddys Laboratories Ltd latest results good or bad?

Dr. Reddy's Laboratories Ltd's latest Q1 FY27 results show a significant sequential profit increase of 101.13% and a revenue rise of 7.33%, but year-on-year net profit and revenue have declined by 68.67% and 5.51%, respectively, with operating margins dropping sharply, indicating underlying challenges. Investors should be cautious due to these mixed signals.

Dr. Reddy's Laboratories Ltd's latest results for Q1 FY27 present a mixed picture. On one hand, the company reported a net profit of ₹444.30 crores, which is a significant sequential increase of 101.13% compared to the previous quarter. Additionally, revenue rose by 7.33% quarter-on-quarter to ₹8,099.80 crores. <BR><BR>However, when looking at year-on-year performance, the situation is concerning. The net profit has declined by 68.67% compared to the same quarter last year, and revenue has also decreased by 5.51% year-on-year. Operating margins have taken a significant hit, dropping from 25.44% in the previous year to just 10.65% in the latest quarter, indicating substantial operational challenges.<BR><BR>The reliance on other income, which accounted for a large portion of profit before tax, raises questions about the sustainability of earnings from core operations. Overall, while there are some positive signs in terms of sequential recovery, the year-on-year declines and margin pressures suggest that the results are more indicative of underlying issues rather than a strong turnaround. Investors should be cautious and monitor future performance closely.

Should I buy, sell or hold Dr Reddys Laboratories Ltd?

How has been the historical performance of Dr Reddy's Labs?

Dr Reddy's Labs has shown consistent growth from Mar'20 to Mar'25, with net sales increasing from 17,517 Cr to 32,643.90 Cr and profit after tax rising from 1,969.90 Cr to 5,703.50 Cr. The company has maintained positive cash flow and expanded its total assets significantly, reflecting strong financial health.

Answer:<BR>The historical performance of Dr Reddy's Labs shows a consistent growth trajectory in net sales, with figures rising from 17,517.00 Cr in Mar'20 to 32,643.90 Cr in Mar'25. Total operating income has mirrored this trend, increasing from 17,517.00 Cr in Mar'20 to 32,643.90 Cr in Mar'25. Operating profit (PBDIT) has also seen significant growth, climbing from 3,091.00 Cr in Mar'20 to 9,644.40 Cr in Mar'25, although the operating profit margin has fluctuated, peaking at 28.42% in Mar'24 before dropping to 26.26% in Mar'25. Profit before tax has increased from 1,829.60 Cr in Mar'20 to 7,657.80 Cr in Mar'25, while profit after tax has risen from 1,969.90 Cr to 5,703.50 Cr over the same period. The company's total assets have grown from 22,005.40 Cr in Mar'20 to 47,594.10 Cr in Mar'25, reflecting a strong balance sheet, while total liabilities have also increased, from 22,005.40 Cr to 47,594.10 Cr. Cash flow from operating activities has shown a positive trend, increasing from 2,984.00 Cr in Mar'20 to 4,642.00 Cr in Mar'25, contributing to a net cash inflow of 748.00 Cr in Mar'25.<BR><BR>Breakdown:<BR>Dr Reddy's Labs has demonstrated robust growth in net sales, which rose from 17,517.00 Cr in Mar'20 to 32,643.90 Cr in Mar'25, indicating a strong demand for its products. The total operating income followed suit, reflecting the same upward trend. Operating profit (PBDIT) has significantly increased, reaching 9,644.40 Cr in Mar'25, although the operating profit margin experienced some volatility. Profit before tax surged to 7,657.80 Cr, while profit after tax reached 5,703.50 Cr, showcasing the company's improving profitability. The total assets of Dr Reddy's Labs expanded considerably, reflecting its growth strategy, while total liabilities also increased, indicating a corresponding rise in financial obligations. The cash flow from operating activities has remained positive, contributing to a net cash inflow, which further underscores the company's solid financial health and operational efficiency.

Is Dr Reddy's Labs technically bullish or bearish?

As of November 28, 2025, Dr Reddy's Labs shows a mildly bullish trend based on daily moving averages and weekly Dow Theory, despite mixed signals from weekly MACD and KST indicators.

As of 28 November 2025, the technical trend for Dr Reddy's Labs has changed from sideways to mildly bullish. The daily moving averages indicate a bullish stance, while the weekly MACD and KST are bearish, suggesting mixed signals. The weekly Dow Theory shows a mildly bullish trend, but the monthly indicators remain mostly bearish or neutral. Overall, the current technical stance is mildly bullish, driven primarily by the daily moving averages and the weekly Dow Theory, despite the bearish signals from MACD and KST on the weekly time frame.

Is Dr Reddy's Labs overvalued or undervalued?

As of October 27, 2025, Dr Reddy's Labs is fairly valued with a PE ratio of 18.57, lower than its peers like Sun Pharma and Divi's Lab, despite recent underperformance compared to the Sensex.

As of 27 October 2025, Dr Reddy's Labs has moved from a very attractive to an attractive valuation grade. The company is currently considered fairly valued. Key ratios include a PE ratio of 18.57, an EV to EBITDA ratio of 11.31, and a Price to Book Value of 0.30, which indicate a reasonable valuation compared to its peers.<BR><BR>In comparison to its peers, Dr Reddy's Labs has a lower PE ratio than Sun Pharma (35.43) and Divi's Lab (74.62), both of which are classified as expensive. Additionally, it is on par with Cipla (PE of 23.74) and Zydus Lifesciences (PE of 21.52), which are also attractive. Despite a recent underperformance relative to the Sensex over the past year, where Dr Reddy's returned -1.40% compared to the Sensex's 6.77%, the valuation metrics suggest that the stock is currently fairly valued in the market.

Who are the top shareholders of the Dr Reddy's Labs?

The top shareholders of Dr Reddy's Labs include promoter G V Prasad with 11.52%, J P Morgan Chase Bank Na as the largest public shareholder at 11.54%, mutual funds holding 12.89%, foreign institutional investors at 25.75%, and individual investors with approximately 8.2%.

The top shareholders of Dr Reddy's Labs include several key players. The majority shareholders are the promoters, with G V Prasad being the promoter with the highest holding at 11.52%. In the public domain, J P Morgan Chase Bank Na holds a significant stake of 11.54%, making it the highest public shareholder. Additionally, mutual funds collectively hold 12.89% through 38 schemes, while foreign institutional investors (FIIs) account for 25.75% with 799 FIIs involved. Individual investors hold around 8.2% of the shares.

When is the next results date for Dr Reddy's Labs?

No Upcoming Board Meetings

What is the bonus history of the Dr Reddy's Labs?

Dr. Reddy's Laboratories issued a 1:1 bonus on August 28, 2006, allowing shareholders to double their holdings by receiving an additional share for each share owned, with the record date set for August 29, 2006.

Dr. Reddy's Laboratories has a bonus history that includes a notable 1:1 bonus issue announced on August 28, 2006. The record date for this bonus was August 29, 2006. This means that for every share held, shareholders received an additional share, effectively doubling their holdings at that time. If you have any more questions about the company or its financials, feel free to ask!

Has Dr Reddy's Labs declared dividend?

Yes, Dr Reddy's Laboratories has declared an 800% dividend, amounting to ₹40 per share, with an ex-date of July 16, 2024. The company has demonstrated strong total returns across various periods, with a total return of 15.2% over the past year.

Dr Reddy's Laboratories Ltd has declared an 800% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 800%<BR>- Amount per share: 40<BR>- Ex-date: 16 Jul 24<BR><BR>Dividend Yield: 0.62%.<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was 5.26%, with no dividend return, resulting in a total return of 5.26%.<BR><BR>Over the past year, the price return was 11.89%, the dividend return was 3.31%, leading to a total return of 15.2%.<BR><BR>In the 2-year period, the price return was 42.35%, the dividend return was 8.21%, culminating in a total return of 50.56%.<BR><BR>For the last 3 years, the price return was 53.12%, with a dividend return of 12.94%, resulting in a total return of 66.06%.<BR><BR>In the 4-year timeframe, the price return was 25.6%, the dividend return was 12.49%, giving a total return of 38.09%.<BR><BR>Lastly, over the past 5 years, the price return was 63.89%, with a dividend return of 20.41%, leading to a total return of 84.3%.<BR><BR>Overall, Dr Reddy's Laboratories has declared a substantial dividend while also showing strong total returns across multiple periods, indicating a positive financial performance for the company.